Latest:
Dr. Joshi on Rationale for Durvalumab/RT Combo in Localized Urothelial Carcinoma
Monika Joshi, MD, discusses the rationale for using durvalumab in combination with radiation therapy in patients with localized urothelial carcinoma.
- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Authors
Moon Chen, PhD
Latest:
Initiative Aims to Boost Clinical Trial Participation Among Asian-Americans
The UC Davis Comprehensive Cancer Center and the National Cancer Institute (NCI)-funded National Center for Reducing Asian American Cancer Health Disparities are working to address these disparities through programs to boost participation in clinical trials, collect biospecimens, and conduct blood genomics research.
Morganna Freeman, DO, FACP
Latest:
Where There’s Smoke: Are Oncology Fellows in Danger of Burnout?
This moment occurred during the middle of my first year of fellowship, and I felt overwhelmed by clinical responsibilities and a seemingly insurmountable learning curve. The question dawned on me: was I suffering from burnout?
Morie Gertz, MD
Latest:
Birtamimab Plus Standard-Of-Care in Light Chain Amyloidosis: The Phase 3 Randomized, Placebo-Controlled VITAL Trial
SPONSORED CONTENT: Morie Gertz, MD, reviews data on the use of birtamimab plus standard-of-care anti-plasma cell chemotherapy in patients with light-chain amyloidosis, which was investigated in the phase 3 randomized, placebo-controlled VITAL trial.
Morris Sherman, MD, PhD
Latest:
Dr. Sherman on Screening Obstacles in Liver Cancer
Morris Sherman, MD, PhD, professor of Medicine at University of Toronto, discusses the issues oncologists face with screening patients for hepatocellular carcinoma (HCC) in an interview during the 10th International Liver Cancer Association (ILCA) Annual Conference.
Moshe Ornstein, MD
Latest:
Optimizing Treatment in Advanced RCC
Martin H. Voss, MD, provides valuable insights into determining the optimal duration of treatment with lenvatinib plus pembrolizumab in patients with advanced renal clear cell carcinoma, emphasizing the importance of close patient monitoring and the critical decision-making process involved in continuing or discontinuing treatment based on individual patient response, tolerability, and overall clinical status in real-world clinical practice settings.
Motzer RJ, Escudier B, Oudard S, et al.
Latest:
Everolimus Improves Progression-Free Survival in Patients with Previously Treated Metastatic RCC
A subgroup analysis of a randomized trial showed that patients with previously treated metastatic renal cell carcinoma had significant improvement in progression-free survival when they received everolimus.
MPH, Kristine Kokeny, MD
Latest:
The Effect of Prostate MRI on Cancer Staging and Radiotherapy Treatment Recommendations
Researchers evaluate the role of magnetic-resonance imaging in the clinical staging of prostate
cancer in the definitive and salvage settings, and to identify changes in treatment recommendations.
Mrinal Patnaik, MBBS
Latest:
Dr. Patnaik on Activity of SL-401 in Chronic Myelomonocytic Leukemia
Mrinal Patnaik, MBBS, hematologist, Mayo Clinic, discusses the encouraging results seen in a phase II trial evaluating the activity of SL-401 in patients with advanced, high risk myeloproliferative neoplasms, including chronic myelomonocytic leukemia.